
Pharmaceutical Biocatalysis
Important Enzymes, Novel Targets, and Therapies
- 460 pages
- English
- ePUB (mobile friendly)
- Available on iOS & Android
About this book
This volume of Pharmaceutical Biocatalysis starts with a discussion on the importance of biocatalytic synthesis approaches for a sustainable and environmentally friendly production of pharmaceuticals and active pharmaceutical ingredients. Among the enzymes discussed in detail with respect to their pharmaceutical relevance are cyclic nucleotide phosphodiesterases playing an important role in modulating signal transduction in various cell types; human DOPA decarboxylase, related to Parkinson's disease and aromatic amino acid decarboxylase deficiency; and phospholipase D enzymes as drug targets. Isocitrate dehydrogenase 1 and 2 mutations are novel therapeutic targets in acute myeloid leukemia. An additional chapter is devoted to the use of enzymes for prodrug activation in cancer therapy. The other topics include small-molecule inhibitors targeting receptor tyrosine kinases in cancer, ?-Lactams and related compounds as antibacterials, non-vitamin K oral anticoagulants for the treatment of thromboembolic diseases, and the molecular mechanisms for statin pleiotropy and its clinical relevance in cardiovascular diseases. The last chapter is a review of lysosomal storage disorders with an overview of approved drugs for treating these disorders by enzyme replacement therapy.
Frequently asked questions
- Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
- Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Information
Table of contents
- Cover
- Half Title
- Series Page
- Title Page
- Copyright Page
- Contents
- Preface
- 1. Lipase-Mediated Biocatalysis as a Greener and Sustainable Choice for Pharmaceutical Processes
- 2. Phosphodiesterases
- 3. Human DOPA Decarboxylase: Catalysis and Involvement in Pharmacological Treatments for Parkinson’s Disease and Aromatic Amino Acid Decarboxylase Deficiency
- 4. Advancing Phospholipase D Enzymes as Diverse Drug Targets
- 5. IDH1 and IDH2 Mutations as Novel Therapeutic Targets in Acute Myeloid Leukemia: Current Perspectives
- 6. Enzymes for Prodrug-Activation in Cancer Therapy
- 7. Small-Molecule Inhibitors Targeting Receptor Tyrosine Kinases in Cancer
- 8. β-Lactams and Related Compounds as Antibacterials and β-Lactamase Inhibitors
- 9. Direct Oral Anticoagulants: New Options
- 10. Molecular Mechanisms for Statin Pleiotropy and Possible Clinical Relevance in Cardiovascular Disease
- 11. Lysosomal Storage Disorders and Enzyme Replacement Therapy
- Index